Health
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
PRINCETON, N.J., October 25, 2025--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/f503bed76220b41facc61d6f604eb4aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BLzxzlAfw1CxMC0BBNPilw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f503bed76220b41facc61d6f604eb4aa","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/aPEXd7cqYtXb05bXd6oGAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f503bed76220b41facc61d6f604eb4aa","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Positive, early results from 71 patients treated across three disease cohorts – systemic sclerosis, systemic lupus erythematosus and idiopathic inflammatory myopathies – are being disclosed","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"Across all cohorts, results support potential for immune reset, with 94% of evaluable patients remaining off chronic immunosuppressive therapy at the time of analysis","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"Results demonstrate BMS’ steady advancement toward its goal of bringing the science of cell therapy beyond blood cancer into autoimmune diseases","length":144,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., October 25, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its investigational, autologous CD19-targeted NEX-T™ CAR T cell therapy BMS-986353 (CC-97540). The data, evaluating a total of 71 treated patients across the systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM) cohorts, are being featured at the American College of Rheumatology (ACR) Convergence 2025, taking place from October 24-29 in Chicago, Illinois.","length":650,"tagName":"p"},{"type":"text","content":"The preliminary Phase 1 safety and efficacy results presented are consistent with the potential for immune reset, as part of a treatment process that includes a one-time infusion of CD19 NEX-T, showing robust CAR T...